According to the Zhitong Finance App, Juzi Biotech (02367.HK) announced its 2026 interim results, with revenue of about 2,918 billion yuan, a decrease of 6.3%; gross profit of about 2,318 billion yuan, a decrease of 8.8%; profit attributable to the company's equity shareholders of about 940 million yuan, a decrease of 20.5% year on year; adjusted net profit of about 945.5 million yuan, a decrease of 21.5% year on year; basic profit per share of 0.89 yuan.

According to the Zhitong Finance App, Juzi Biotech (02367.HK) announced its 2026 interim results, with revenue of about 2,918 billion yuan, a decrease of 6.3%; gross profit of about 2,318 billion yuan, a decrease of 8.8%; profit attributable to the company's equity shareholders of about 940 million yuan, a decrease of 20.5% year on year; adjusted net profit of about 945.5 million yuan, a decrease of 21.5% year on year; basic profit per share of 0.89 yuan.